AI Article Synopsis
- Desmoplastic small round cell tumor (DSRCT) is a rare cancer first identified in 1989, characterized by a specific genetic abnormality (EWS/WT1 fusion) that helps in its diagnosis.
- The prognosis for DSRCT is quite grim, with up to 90% of patients facing fatal outcomes, and treatment effectiveness does not significantly differ based on the timing of surgery relative to chemotherapy.
- Effective management of DSRCT necessitates an aggressive approach that includes various treatment modalities (multimodality therapy).
Article Abstract
Desmoplastic small round cell tumor (DSRCT) is a rare tumor that was first described by Gerald and Rosai in 1989 as a mesenchymal entity. This tumor has a unique translocation t (11:22) (p:13, q:12) resulting in EWS/WT1 gene fusion that is diagnostic for DSCRT. The overall prognosis for desmoplastic small round cell tumor remains extremely poor, with reported rates of death as high as 90%. Although the majority of patients undergo chemotherapy following surgery, the prognosis has been shown to be independent of whether the surgical process preceded or followed chemotherapy. In this review, we provide insights for the management of DSCRT that requires aggressive multimodality therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-017-0638-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!